Press Release.
London, UK. September 30 2015
Advent Life Sciences announced today the appointment of Roy Lobb as Venture Partner. Roy brings over 25 years of biotechnology industry experience with an outstanding record as a scientist and company founder. Following a career at Biogen where he led the discovery of a new cell adhesion pathway that became the basis of the development of TysabriTM, Roy co-founded Albor Biologics, Avila Therapeutics and Alvos Therapeutics. Roy received a DPhil from Oxford University, and completed post-doctoral research at Harvard Medical School, where he was a faculty member before joining Biogen. Raj Parekh, General Partner, said
“Roy’s record of innovation and his scientific judgement will be of real value to us as we look to create a new generation of biotech companies – we welcome Roy to the Team.” Roy Lobb commented “The Advent team has consistently focussed on supporting insightful new approaches to medical discovery, and I am excited by the opportunity to work closely with them to found and grow innovative new companies.”
– Ends –
About Advent Life Sciences.
Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of 16 professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe, and is particularly focussed on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The Firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France.
For more information, please visit AdventLS.com
Contact : Advent Life Sciences
Melanie McIntosh
Phone : +44 (0)207 932 2100
email : melanie@adventLS.com
